Slide 1: 2Q25 Financial Results and Business Update
2Q25 Financial Results and Business Update August 12, 2025 1
Slide 2: Forward-looking statements
This presentation contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “aim,” “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,” “would,” or “will,”
Slide 3: Leader in an expansive global market
Leader in an expansive global market Focused on detecting Galleri® is routinely detecting cancer early, when it can be cured1 asymptomatic deadly cancers today • Current recommended screening • >45,000 tests sold in Q2’25 is limited, and most asymptomatic deadly cancers are • >370,000 commercial Gal
Slide 4: Positive top-line results from both registrational studies
Positive top-line results from both registrational studies NHS-Galleri PATHFINDER 2 (Prevalent screening round, announced May 13) (First 25k enrolled, announced June 18) • Substantially higher PPV than the 43% observed in the • Adding Galleri to standard of care screening first PATHFINDER study demo
Slide 5: Robust Galleri adoption and strong partnerships
Robust Galleri adoption and strong partnerships Galleri tests sold ~137k ~94k ~83k ~49k ~11k 2021 2022 2023 2024 1H’25 5
Slide 6: Financials
Financials Revenue Projected U.S. Galleri sales 2025 U.S. Galleri Total Q2'25 $34M (+21% YoY) $36M (+11%) 20 - 30% growth Q1’25 $29M (+22%) $32M (+19%) FY’24 $109M (+45%) $126M (+35%) Projected cash burn 2025 Cash balance <$310M • $606M as of June 30, 20251 • Runway into 2028 1 Cash, c ash equivalen
Slide 7: Future milestones to drive shareholder value
Future milestones to drive shareholder value Our strategic priorities are to seek FDA approval of Galleri and pursue CMS coverage & broad commercial reimbursement for Galleri Upcoming catalysts • Planning to submit detailed registrational performance & safety data for presentation at ESMO Congress 2
Slide 8: Q&A
Q&A Advancing towards our vision of population-scale multi-cancer early detection CONFIDENTI AL & PROPRIETARY 8